Timeline

Selene Di Carlo
Research Engineer
06 Oct 2023
news

New publication – Depletion of slow-cycling PDGFRα+ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis.

Read more
05 Oct 2023
publication

Depletion of slow-cycling PDGFRα+ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis.

Read more
30 Jan 2023
news

New publication – Stromal regulation of the intestinal barrier

Read more
25 Jan 2023
publication

Stromal regulation of the intestinal barrier.

Read more
06 May 2022
news

New publication – PDGFRα-induced stromal maturation is required to restrain postnatal intestinal epithelial stemness and promote defense mechanisms

Read more
05 May 2022
publication

PDGFRα-induced stromal maturation is required to restrain postnatal intestinal epithelial stemness and promote defense mechanisms.

Read more
21 Jul 2019
project

Targeting the tumor stromal microenvironment

Read more
02 Jan 2018
publication

The perivascular origin of pathological fibroblasts

Read more
14 May 2016
publication

B cells promote tumor progression in a mouse model of HPV-mediated cervical cancer

Read more
16 Jul 2015
team

Stroma, Inflammation and Tissue Repair

Read more
16 Apr 2015
publication

ATM kinase sustains HER2 tumorigenicity in breast cancer

Read more
20 Feb 2015
publication

Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells

Read more
06 Dec 2012
publication

Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells

Read more
29 Jul 2012
publication

Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury

Read more
30 Jun 2009
publication

Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression

Read more
13 Feb 2008
publication

Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas

Read more